Watch Live

Tweet TWEET

Announcements, Studies, and Corporate Updates by Healthcare Companies - Research Report on Horizon Pharma, Novavax, WuXi

   Announcements, Studies, and Corporate Updates by Healthcare Companies -
     Research Report on Horizon Pharma, Novavax, WuXi PharmaTech, Chelsea
                     Therapeutics, and Anika Therapeutics

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, December 24, 2013

NEW YORK, December 24, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Horizon
Pharma, Inc. (NASDAQ: HZNP), Novavax, Inc. (NASDAQ: NVAX), WuXi PharmaTech
(Cayman) Inc. (NYSE: WX), Chelsea Therapeutics International Ltd. (NASDAQ:
CHTP), and Anika Therapeutics Inc. (NASDAQ: ANIK). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Horizon Pharma, Inc. Research Report

On December 19, 2013, Horizon Pharma, Inc. (Horizon Pharma) announced that on
December 18, 2013, the Compensation Committee of the Company's Board of
Directors has approved the grant of inducement stock options to purchase an
aggregate of 88,000 shares of common stock to 22 new employees. According to
the Company, each stock option has an exercise price of $6.78 per share.
Horizon Pharma further stated that each stock option has a ten year term and
is subject to the terms and conditions of the Company's 2011 Equity Incentive
Plan and the stock option agreement pursuant to which the option was granted.
The Full Research Report on Horizon Pharma, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/05ea_HZNP

--

Novavax, Inc. Research Report

On December 19, 2013, Novavax, Inc.'s (Novavax) stock reflected an increase of
3.77%, and closed the day at $4.68 per share. Over the period of past three
trading days, the Company's stock increased by 1.52%, compared to the Dow
Jones Industrial Average which went up by 1.85%, and the Nasdaq composite
which went up by 0.71%, over the same three day trading period. The Full
Research Report on Novavax, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/bc35_NVAX

--

WuXi PharmaTech (Cayman) Inc. Research Report

On December 19, 2013, WuXi PharmaTech (Cayman) Inc.'s (WuXi PharmaTech) stock
was up by 3.55%, closing the day at $35.61 per share. Over the past three-day
trading period, the Company's stock went up by 8.37%, compared to S&P 500
which went up by 1.29% during the same three-day trading period. The Full
Research Report on WuXi PharmaTech (Cayman) Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/df7b_WX

--

Chelsea Therapeutics International Ltd. Research Report

On December 9, 2013, Chelsea Therapeutics International Ltd. (Chelsea
Therapeutics) announced that the first patient has been dosed in Study 401, a
multi-center, multi-national, randomized, parallel-group, placebo-controlled,
double-blind study of investigational drug NORTHERA™ (droxidopa). The Company
reported that NORTHERA is an orally active synthetic precursor of
norepinephrine, being studied for the treatment of symptomatic neurogenic
orthostatic hypotension (nOH) in patients with primary autonomic failure (such
as Parkinson's disease, multiple system atrophy and pure autonomic failure),
dopamine beta hydroxylase deficiency and non-diabetic autonomic neuropathy.
According to Chelsea Therapeutics, the Company expects Study 401 to enroll
approximately 450 patients. Additionally, Joseph G. Oliveto, Interim CEO of
the Company, stated, "Chelsea is committed to understanding the long-term
safety and durability of Northera in symptomatic nOH, a goal we hope to
achieve through Study 401, the largest randomized, placebo-controlled study
undertaken in this orphan indication." Oliveto added, "We thank the many
investigators who have committed to participating in this global study, as
well as the patients and their families who will take part in it. There exists
a significant unmet need in nOH, and it remains Chelsea's goal to bring new
treatment options to those suffering from this debilitating condition." The
Full Research Report on Chelsea Therapeutics International Ltd. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/c6ad_CHTP

--

Anika Therapeutics Inc. Research Report

On December 19, 2013, Anika Therapeutics Inc.'s (Anika Therapeutics) stock
went up by 3.45% at $35.69 per share. The Company's stock went up by 5.16%
over the past three-day trading period, compared to the Dow Jones Industrial
Average which went up by 1.85%, and the Nasdaq composite which went up by
0.71%, during the same trading period. The Full Research Report on Anika
Therapeutics Inc.- including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/ae5d_ANIK

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.